Wegovy Doses: FDA-Label Range and Titration

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Questions about Wegovy doses usually come down to two things: what doses exist and why the schedule ramps up slowly. This article reports the label-level facts and the reasoning behind titration, without recommending any schedule. Dose decisions belong with your provider. For wider GLP-1 context, browse the Education Hub.

The FDA-label dose range

Per the Wegovy FDA label, dosing begins at a 0.25 mg starting dose and is titrated to a maintenance dose of 2.4 mg per week. Wegovy is administered as a once-weekly subcutaneous injection. The label describes a graduated concept: begin at the lowest dose so the body can adapt to GLP-1 pathway activation, then increase under prescriber supervision based on tolerability and response.

The once-weekly format

The once-weekly subcutaneous format is part of what defines Wegovy's dosing. The full administration protocol — timing, storage, and technique guidance where applicable — lives in the FDA label and the patient information leaflet that ships with the medication. Your prescriber and pharmacist walk you through it; this page does not substitute for that.

Why the schedule ramps slowly

Gradual titration is the standard approach across the GLP-1 class because gastrointestinal side effects, nausea in particular, are most pronounced during dose escalation. The label's graduated schedule is designed to blunt intolerable symptoms while maintaining therapeutic momentum. Skipping or accelerating titration is associated with higher discontinuation rates in real-world data.

What providers weigh in dose decisions

Dose selection, titration speed, and adjustments are individualized clinical calls. Providers typically consider baseline metabolic status, kidney function, gastrointestinal history, prior medication tolerability, and the FDA-approved indication on the prescription. The consistent rule across the class: never adjust GLP-1 receptor agonist dosing on your own.

Where PlexusDx fits

PlexusDx offers semaglutide through its Weight Management Protocols, including the Semaglutide Injection and Semaglutide Oral protocols. What distinguishes the approach is the upstream context supplied before any protocol conversation, rather than the dosing mechanics themselves, which remain a prescriber's domain.

The titration concept in plain terms

Titration is often described in clinical shorthand, but the underlying idea is simple: start low, let the body adjust, then move up only as tolerance allows. The FDA label frames Wegovy around that concept precisely because the GLP-1 pathway takes time to adapt to. Beginning at the lowest dose gives the gastrointestinal system a chance to acclimate before the maintenance dose is reached, which is why the schedule is graduated rather than immediate. The reasoning is not arbitrary — it reflects consistent experience across the GLP-1 class that tolerability improves when escalation is gradual. Importantly, the concept is about pacing, not about a schedule you set yourself; the prescriber owns the timing and adjusts it to how you respond.

What the once-weekly rhythm means in practice

The once-weekly subcutaneous format shapes how the medication fits into a routine. Unlike a daily medication, a weekly cadence means the rhythm of administration, storage, and follow-up is built around a single recurring point rather than a daily one. The practical details — when in the week, how to store the medication, and any handling guidance — are documented in the FDA label and the patient information leaflet, and your prescriber and pharmacist review them before you begin. Because this page reports label-level facts rather than instructions, the takeaway is conceptual: a weekly format is designed to deliver sustained receptor engagement while keeping the administration burden low, and the specifics of carrying it out belong to the clinical relationship, not to a webpage.

The genetics upstream of dosing

Dose response is influenced by biology that predates any prescription. Variants in GLP1R, the GLP-1 receptor gene, along with FTO and MC4R, shape baseline appetite, receptor engagement, and energy balance. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights to map those tendencies. It never predicts dose response or titration tolerability; it is context for the broader conversation.

Frequently Asked Questions

What is the Wegovy dose range on the FDA label?

Per the Wegovy FDA label, dosing starts at 0.25 mg and is titrated to a maintenance dose of 2.4 mg per week, delivered as a once-weekly subcutaneous injection. Specific dose selection and titration speed are individualized clinical decisions. Follow the schedule your prescriber sets and never adjust GLP-1 dosing on your own.

How often is Wegovy administered?

Wegovy is administered once weekly as a subcutaneous injection. The complete administration protocol, including timing, storage, and any technique guidance, appears in the FDA label and the patient information leaflet included with the medication. Your prescriber and pharmacist review the details with you before you begin.

Why does Wegovy titrate up gradually?

The graduated schedule exists to reduce gastrointestinal side effects — nausea, vomiting, diarrhea — that are most pronounced during dose escalation. Ramping slowly lets the body adapt to GLP-1 pathway activation and improves tolerability. Real-world data link skipped or accelerated titration to higher discontinuation rates.

Can a genetic test guide my Wegovy dose?

No. The Precision Peptide Genetic Test does not predict dose response or titration tolerability. It analyzes pathway-level variants in genes like FTO, and MC4R that shape baseline GLP-1 biology — context for a provider conversation about the broader protocol, not a dose-selection tool.

Start with the biology beneath the schedule. Explore the Education Hub or the Weight Management Protocols.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.